Euronext-listed biotech company TiGenix supports seed round of its spin-out, TR-therapeutics, after its merger with Therosteon to form Arcarios.
Netherlands-based biotech company Arcarios has gained its seed round from a large consortium of strategic and venture investors.
Arcarios was formed through a merger of Therosteon and a spin -off from Euronext-listed biotech company TiGenix alongside Dutch universities in Ghent and Leuven.
Venture capital (VC) firm BioGeneration Ventures led the undisclosed amount of funding for Arcarios, which is looking for disease-modifying therapeutics of bone and joint diseases.
BioGeneration Ventures was co-founded by the Netherlands Genomics Initiative, the University of Leiden’s NOW organisation…
